Hsbc Holdings PLC Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• HSBC Holdings purchased 109,320 shares of BioCryst Pharmaceuticals in the second quarter, valued at approximately $1.1 million. Institutional investors collectively own 85.88% of BCRX, with major holders including BlackRock, Vanguard, and RA Capital.
• BioCryst reported quarterly EPS of $0.30, beating analyst estimates of $0.15, while revenue rose 33.6% year over year to $218.25 million. Despite the improvement, the company continues to post negative net margins and analysts forecast a full-year loss.
• Analysts maintain a generally positive view, with eight Buy ratings and four Holds, producing a “Moderate Buy” consensus and an average price target of $20.60 versus the stock’s recent price of $9.70.

Hsbc Holdings PLC purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 109,320 shares of the biotechnology company's stock, valued at approximately $1,079,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in BioCryst Pharmaceuticals in the second quarter worth $238,930,000. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company's stock valued at $173,732,000 after buying an additional 482,494 shares during the period. RA Capital Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. boosted its holdings in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company's stock valued at $92,363,000 after buying an additional 7,477,000 shares in the last quarter. Finally, State Street Corp grew its position in shares of BioCryst Pharmaceuticals by 12.9% in the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company's stock worth $86,371,000 after buying an additional 1,265,773 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 1.2%

NASDAQ BCRX opened at $9.70 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.22. The stock's fifty day moving average price is $9.73 and its 200-day moving average price is $9.09. The stock has a market cap of $2.48 billion, a P/E ratio of -6.47 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analysts' expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals's revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.15 EPS. As a group, analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several research reports. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating for the company in a research note on Thursday, August 6th. HC Wainwright reissued a "buy" rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Royal Bank Of Canada cut their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Finally, Needham & Company LLC lowered their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.